Photo by apchf from unsplash
One of the latest automated insulin Delivery (AID) systems is the advanced hybrid closed-loop (AHCL), the MiniMed 780G system (Medtronic, Northridge, CA, USA), which automatically delivers basal insulin with a… Click to show full abstract
One of the latest automated insulin Delivery (AID) systems is the advanced hybrid closed-loop (AHCL), the MiniMed 780G system (Medtronic, Northridge, CA, USA), which automatically delivers basal insulin with a customizable glucose target in addition to automated bolus correction, as required. Several studies [1–3] have shown that AID systems in people with type 1 diabetes (T1D) previously treated with insulin pump therapy can improve HbA1c and reduce time in hyperglycemia without increasing hypoglycemia. To the best of our knowledge, this is the first clinical experience on AHCL MiniMed 780G system in people with T1D, previously treated with multiple daily injections (MDI), without prior pump experience. The objective of this study was to evaluate the glycemic outcome using AHCL Minimed 780G system in children and adolescents with T1D on MDI therapy.
Journal Title: Acta Diabetologica
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!